LILLY ELI & CO (LLY) |
Consensus Forecast of LILLY ELI and CO Revenue in Millions  |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
11/07 |
| $18,633.50 |
$20,378.00 |
$21,836.00 |
$22,922.10 |
$22,799.80 |
5.2% |
|
| Consensus Forecast of LILLY ELI and CO EPS |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| $2.87 |
$3.18 |
$3.54 |
$4.02 |
$4.42 |
$4.49 |
$4.45 |
$3.81 |
|
EPS FORECASTS
|
This section is designed to find errors as the consensus forecast of EPS. The consensus forecasts for the lines in the LILLY ELI & CO Income Statement are shown and below each consensus forecast is a wiki section to discuss why the consensus forecast of that item may be high or low
|
|
| Consensus Forecasts of Total Revenue |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
12/05 |
| 1. Total Revenue |
$14,645.0 |
$15,735.5 |
$18,644.1 |
$20,426.2 |
$21,806.1 |
$22,915.4 |
$22,866.5 |
$21,560.7 |
5.7% |
|
| Discussion by Wiki Users | | Outlook: Revenue growth is now expected in low single digits due to favorable movement of foreign currency. The company was previously expecting revenue growth to be flat or slightly up from the 2010 levels. Zyprexa sales will erode rapidly with the entry of generics. US exclusivity is scheduled to expire in October 2011. Moreover, Gemzar will continue facing rapid erosion in the US due to genericization. Meanwhile, Strattera generics are not expected to enter the US market in 2011. Alimta, Cialis, Cymbalta, Effient, Humalog and animal health products are expected to help offset the impact of genericization.
| Last edited Mon Jun 06, 2011 02:15 AM
by SreelaBose (Zacks Investment Research) |  |
| Consensus Forecasts of Fully Diluted Shares Outstanding |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| Fully Diluted Shares Outstanding |
1091.0 |
1087.1 |
1090.8 |
1094.8 |
1097.9 |
1102.1 |
1099.1 |
1098.0 |
|
| Consensus Forecasts of GAAP EPS |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| GAAP EPS |
$1.8 |
$2.5 |
$2.7 |
($1.9) |
$4.0 |
$4.5 |
$4.4 |
|
|
| Discussion by Wiki Users | | 2011 Outlook:
Lilly expects to earn $4.15 - $4.30 per share in 2011, down 9%-12% from 2010. 2011 will be a challenging year for Eli Lilly with the company losing patent exclusivity on Zyprexa. Zyprexa sales will erode rapidly with the entry of generics. Moreover, Gemzar will continue facing rapid erosion due to genericization. Meanwhile, Strattera generics are not expected to enter the US market in 2011. However, a couple of firms expect Strattera generics to enter the market in 2011.
| Last edited Mon Jun 06, 2011 02:18 AM
by SreelaBose (Zacks Investment Research) | |
| Consensus Forecasts of Cost of Goods Sold |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 2. Cost of Goods Sold |
$3,474.0 |
$3,559.9 |
$4,253.4 |
$4,365.5 |
$4,246.9 |
$4,579.3 |
$4,698.3 |
$4,664.3 |
| Percent of Revenue |
24% |
23% |
23% |
21% |
19% |
20% |
21% |
22% |
| 3. Gross Profit (1-2) |
$11,171.00 |
$12,175.60 |
$14,390.70 |
$16,060.70 |
$17,559.20 |
$18,336.10 |
$18,168.20 |
$16,896.40 |
| Percent of Revenue |
76% |
77% |
77% |
79% |
81% |
80% |
79% |
78% |
|
| Consensus Forecasts of Selling, General and Administrative Expense |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 4. Selling, General and Administrative Expense |
$4,497.0 |
$4,917.8 |
$6,105.1 |
$6,637.6 |
$6,892.7 |
$7,058.6 |
$6,890.2 |
$6,523.6 |
| Percent of Revenue |
31% |
31% |
33% |
32% |
32% |
31% |
30% |
30% |
|
| Discussion by Wiki Users | |
| Last edited Fri May 14, 2010 03:26 AM
by SudiptaMukherjee (Zacks Investment Research) | |
| Consensus Forecasts of Research and Development |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 5. Research and Development |
$3,026.0 |
$3,137.8 |
$3,531.6 |
$3,854.3 |
$4,326.7 |
$4,776.6 |
$4,957.4 |
$4,880.9 |
| Percent of Revenue |
21% |
20% |
19% |
19% |
20% |
21% |
22% |
23% |
|
| Discussion by Wiki Users | |
| Last edited Fri May 14, 2010 03:26 AM
by SudiptaMukherjee (Zacks Investment Research) | |
| Consensus Forecasts of Pre - Tax Income |
| |
Dec-05 |
Dec-06 |
Dec-07 |
Dec-08 |
Dec-09 |
Dec-10 |
Dec-11 |
Dec-12 |
| 7. Pre - Tax Income |
$3,963.0 |
$4,347.0 |
$4,919.5 |
$5,533.7 |
$6,145.0 |
$6,458.6 |
$6,360.4 |
$5,597.9 |
| 8. Tax provisions |
$832.0 |
$898.9 |
$1,049.7 |
$1,175.7 |
$1,289.8 |
$1,500.1 |
$1,437.8 |
$1,309.4 |
| Percent of Revenue |
21% |
21% |
21% |
21% |
21% |
23% |
23% |
23% |
| 9. Net Income (7-8) |
$3,131.00 |
$3,448.10 |
$3,869.80 |
$4,358.00 |
$4,855.20 |
$4,958.50 |
$4,922.60 |
$4,288.50 |
|
| Discussion by Wiki Users | |
| Last edited Fri May 14, 2010 03:26 AM
by SudiptaMukherjee (Zacks Investment Research) | |
| LLY (LILLY ELI & CO) |
$22,275.00 |
$4,263.80 |
50.3% |
-0% |
7.30 |
1.7 |
6.1 |
Industry Mean |
|
|
28% |
5% |
10.40 |
2.7 |
9.3 |
| S&P 500 |
|
|
23% |
11% |
13.71
| 1.9 |
|
|
|
|
|
|
|
|
|
BMY (BRISTOL-MYERS) |
$20,711.00 |
$10,717.00 |
27.8% |
1% |
10.70 |
1.9 |
10.4 |
ABT (ABBOTT LABS) |
$31,744.00 |
$5,310.00 |
27.8% |
12% |
11.44 |
2.3 |
9.2 |
MRK (MERCK & CO INC) |
$33,465.00 |
$11,775.10 |
38.3% |
5% |
9.98 |
3.1 |
11.2 |
CF is operating cash flow plus after-tax interest expense. |
|
| Discussion of Relative Valuation | | No comments yet. Be the first | | |
|
|
| | |
Created by: WikiMigrationBot.
Last Modification: Thursday 03 of June, 2010 08:01:01 CDT by WikiMigrationBot.
|
